Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has consistently shown robust body weight reduction in adults with obesity and overweight, with or without type 2 diabetes in the SURMOUNT trials
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers
But in the United States, its in a fierce competition
Dermatologica Sinica 2023, [Epub ahead of print]:[cited 2023 Mar 2021] Available from: Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Falck-Ytter Y, Jaeschke R, Vist G, et al
Get Started Today Klinic simplifies starting your semaglutide weight loss journey